The story of Sildenafil presents a challenging picture for investors. While the initial launch generated significant returns, the expiration of its patent opened the floodgates to cheaper alternatives, dramatically https://sound-social.com/story11963676/sildenafil-and-big-pharma-a-volatile-bet